No profile data available.
Ascentage Pharma Group International (AAPG) is a healthcare company in the blood cancer treatment drugs industry, based in Suzhou, China, with about 828 full-time employees.
It reported revenue of 574.12 million CNY for fiscal year 2025, down 41.5% from fiscal year 2024, and net income of -1.24 billion CNY. Its market capitalization was $1.38 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
Ascentage Pharma Group International reported 574.12 million CNY in revenue for fiscal year 2025, down 41.5% from 980.65 million CNY in fiscal year 2024.
$1.38 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include Genmab A/S (GMAB), Legend Biotech Corporation (LEGN), Sellas Life Sciences Group, Inc. (SLS), Vor Biopharma Inc. (VOR).